

Supplementary




Figure S1 Blood and coagulation tests values among survivors and non-survivors. Lymphocytes (A,B), Neutrophils (C,D), Prothrombin activity (E,F) and D-Dimer (G,H) are expressed as mean and standard deviation (error bars).




Figure S2 Inflammatory markers among survivors and non-survivors. Lactate Dehydrogenase (A,B), Ferritin (C,D) and C reactive protein (E,F) are expressed as mean and standard deviation (error bars).




Figure S3 Blood and coagulation tests values according to tocilizumab treatment. Lymphocytes (A,B), Neutrophils (C,D), Prothrombin activity (E,F) and D-Dimer (G,H) are expressed as mean and standard deviation (error bars).




Figure S4 Inflammatory markers according to tocilizumab treatment. Lactate Dehydrogenase (A,B), Ferritin (C,D) and C reactive protein (E,F) are expressed as mean and standard deviation (error bars).

Table S1 Correlations among the inflammatory parameters

Parameter	Correlation coefficient (r)	P value
Admission IL-6		
Day 0 CRP	0.332	0.007
Day 1 CRP	0.303	0.015
Day 0 IL-6		
Day 0 CRP	0.297	0.003
Day 0 ferritin	0.539	0.008
Day 1 CRP		
Admission RDW	0.186	0.026
Day 0 RDW	0.275	0.002
Day 1 RDW	0.255	0.04
Day 3 RDW	0.277	0.001
Day 3 CRP		
Day 0 RDW	0.188	0.03
Day 1 RDW	0.245	0.001
Day 3 RDW	0.266	0.001
Day 7 CRP		
Day 7 RDW	0.218	0.017

CRP, C reactive protein; RDW, red blood distribution width.